Galena Biopharma Enrolls First Patient In GALE-301 (Folate Binding Protein (FBP)) Cancer Immunotherapy Phase 2 Clinical Trial In Ovarian Cancer

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PORTLAND, Ore., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the first patient has been enrolled in the Phase 2 trial for GALE-301 (Folate Binding Protein (FBP) vaccine). GALE-301 is a folate receptor alpha-derived, peptide-based cancer immunotherapy administered to HLA-A2 positive patients in combination with granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant treatment to prevent recurrences in high-risk, endometrial and ovarian cancer patients rendered disease-free after completing standard of care therapy.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC